U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H17F3N2O5
Molecular Weight 422.3554
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-0767

SMILES

COc1ccc(cc1C(=NCc2ccc(cc2)C(F)(F)F)O)CC3C(=NC(=O)O3)O

InChI

InChIKey=ORZMUVMQJPGFOM-UHFFFAOYSA-N
InChI=1S/C20H17F3N2O5/c1-29-15-7-4-12(9-16-18(27)25-19(28)30-16)8-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)

HIDE SMILES / InChI

Molecular Formula C20H17F3N2O5
Molecular Weight 422.3554
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

MK-0767 is a potent hypoglycaemic insulin sensitizer being evaluated by Kyorin with potential as an antidiabetic agent. MK-0767 acts as a dual agonist of the peroxisome proliferator-activated receptors alpha and gamma, induced high-affinity interactions of PPARα and PPARγ with the transcriptional coactivator CBP in vitro. In ob/ob mice, MK-0767 normalized hyperglycemia and hyperinsulinemia with equal or greater potency and efficacy than pioglitazone. Treatment of hamsters with MK-0767 produced substantial reductions in blood cholesterol and triglycerides. In dogs, MK-0767 reduced serum cholesterol levels with a potency more than 10-fold greater than simvastatin. The efficacies of MK-0767 and simvastatin were additive when given together.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
83.0 nM [EC50]
140.0 nM [EC50]
PubMed

PubMed

TitleDatePubMed
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
1998 Dec
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
1999 Feb 22
Fatty-acyl-CoA thioesters inhibit recruitment of steroid receptor co-activator 1 to alpha and gamma isoforms of peroxisome-proliferator-activated receptors by competing with agonists.
2001 Jan 15
[KRP-297, MCC-555].
2001 Nov
MK-767. Kyorin/Banyu/Merck.
2003 Apr
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
2003 May
MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
2004 May 28
Patents

Sample Use Guides

0.3-25 mg of MK-0767 were administered once daily for 14 days.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:24:15 UTC 2021
Edited
by admin
on Sat Jun 26 06:24:15 UTC 2021
Record UNII
Y180U02GSB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-0767
Common Name English
BENZAMIDE, 5-((2,4-DIOXO-5-OXAZOLIDINYL)METHYL)-2-METHOXY-N-((4-(TRIFLUOROMETHYL)PHENYL)METHYL)-
Systematic Name English
MK0767
Common Name English
Code System Code Type Description
CAS
934017-32-0
Created by admin on Sat Jun 26 06:24:16 UTC 2021 , Edited by admin on Sat Jun 26 06:24:16 UTC 2021
PRIMARY
FDA UNII
Y180U02GSB
Created by admin on Sat Jun 26 06:24:16 UTC 2021 , Edited by admin on Sat Jun 26 06:24:16 UTC 2021
PRIMARY
DRUG BANK
DB12055
Created by admin on Sat Jun 26 06:24:16 UTC 2021 , Edited by admin on Sat Jun 26 06:24:16 UTC 2021
PRIMARY
PUBCHEM
56842109
Created by admin on Sat Jun 26 06:24:16 UTC 2021 , Edited by admin on Sat Jun 26 06:24:16 UTC 2021
PRIMARY
Related Record Type Details
ACTIVE MOIETY